How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Richard Socher's new $650 million startup wants to build an AI that can research and improve itself indefinitely — and he ...
Christina Majaski writes and edits finance, credit cards, and travel content. She has 14+ years of experience with print and digital publications. Khadija Khartit is a strategy, investment, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results